- Home
- RDI vs TPST Comparison
RDI vs TPST Comparison
Compare RDI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- TPST
- Stock Information
- Founded
- RDI 1937
- TPST 2011
- Country
- RDI United States
- TPST United States
- Employees
- RDI N/A
- TPST N/A
- Industry
- RDI Movies/Entertainment
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- TPST Health Care
- Exchange
- RDI Nasdaq
- TPST Nasdaq
- Market Cap
- RDI 30.1M
- TPST 24.5M
- IPO Year
- RDI N/A
- TPST N/A
- Fundamental
- Price
- RDI $1.38
- TPST $5.95
- Analyst Decision
- RDI Hold
- TPST Hold
- Analyst Count
- RDI 1
- TPST 3
- Target Price
- RDI $2.40
- TPST $30.00
- AVG Volume (30 Days)
- RDI 38.2K
- TPST 40.2K
- Earning Date
- RDI 05-15-2025
- TPST 05-13-2025
- Dividend Yield
- RDI N/A
- TPST N/A
- EPS Growth
- RDI N/A
- TPST N/A
- EPS
- RDI N/A
- TPST N/A
- Revenue
- RDI $205,644,000.00
- TPST N/A
- Revenue This Year
- RDI $9.74
- TPST N/A
- Revenue Next Year
- RDI $6.39
- TPST N/A
- P/E Ratio
- RDI N/A
- TPST N/A
- Revenue Growth
- RDI N/A
- TPST N/A
- 52 Week Low
- RDI $1.17
- TPST $5.35
- 52 Week High
- RDI $1.89
- TPST $47.45
- Technical
- Relative Strength Index (RSI)
- RDI 52.10
- TPST 35.03
- Support Level
- RDI $1.34
- TPST $6.11
- Resistance Level
- RDI $1.49
- TPST $6.44
- Average True Range (ATR)
- RDI 0.08
- TPST 0.34
- MACD
- RDI 0.00
- TPST 0.02
- Stochastic Oscillator
- RDI 32.35
- TPST 2.84
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.